10-Q: Neogen Corp. Q3 2026 Earnings: Revenue Dip, Genomics Sale Planned

Neogen Corporation reported a revenue decrease for the third quarter of fiscal year 2026, driven by divestitures, while also announcing plans to sell its genomics business.

Summary

• Neogen Corporation reported total revenues of $211.2 million for the third quarter ended February 28, 2026, a decrease of $9.8 million compared to the same period last year.
• For the nine-month period ended February 28, 2026, total revenues were $645.1 million, down $24.1 million from the prior year.
• The company recorded a net loss of $17.0 million for the third quarter, compared to a net loss of $10.9 million in the prior year's quarter.
• For the nine-month period, Neogen reported a net income of $3.4 million, a significant improvement from a net loss of $479.8 million in the prior year.
• Neogen announced a definitive agreement to sell its Genomics business to Zoetis Inc. for $160.0 million, expected to close by the end of the first half of fiscal year 2027.
• The company is implementing a restructuring plan to reduce its global headcount by approximately 10% to right-size its cost base.
• Material weaknesses in internal control over financial reporting were identified, and remediation efforts are underway.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to declining revenues, increased net loss in the current quarter, and ongoing operational challenges, despite the strategic sale of the genomics business and year-to-date net income improvement.

Positives

• Net income for the nine-month period improved significantly to $3.4 million from a $479.8 million net loss in the prior year, largely due to a $76.4 million gain on the sale of the Cleaners and Disinfectants business.
• The Food Safety segment revenue increased by 2.6% to $156.7 million in the third quarter, driven by growth in pathogen detection, indicator sales, and sample collection products.
• International sales showed a slight increase of $3.3 million to $108.9 million in the third quarter.
• Cash provided by operating activities increased by $11.2 million to $53.0 million for the nine-month period.
• Cash provided by investing activities increased significantly by $157.8 million to $74.5 million for the nine-month period, primarily due to proceeds from the sale of the Cleaners and Disinfectants business.

Negatives

• Total revenues decreased by $9.8 million to $211.2 million in the third quarter and by $24.1 million to $645.1 million for the nine-month period, largely due to divestitures and discontinued product lines.
• The Animal Safety segment revenue decreased by 20.1% to $54.5 million in the third quarter and by 11.5% to $170.8 million for the nine-month period.
• Gross margin decreased to 46.9% in the third quarter from 49.9% in the prior year, attributed to volume decreases, higher inventory write-offs, and duplicative manufacturing costs.
• The company reported a net loss of $17.0 million for the third quarter, compared to a net loss of $10.9 million in the prior year.
• General and administrative expenses increased in both comparable periods, driven by investments in transformation initiatives and transaction costs.
• Material weaknesses in internal control over financial reporting were disclosed, indicating potential issues with timely detection of misstatements.

Risks

• Integration challenges and performance of acquired or transitioned businesses.
• Execution risks associated with manufacturing transitions, including Petrifilm, and related product qualifications.
• Dependence on and qualification of third-party suppliers, logistics partners, and package delivery services.
• Timing, terms, and outcome of portfolio actions, including the genomics business divestiture.
• Ability to realize expected cost savings, transformation initiatives, and operational efficiencies.
• Changes in customer demand, competitive dynamics, market acceptance, and pricing.
• Regulatory, legal, tax, and trade developments, including tariffs and export/import restrictions.
• Risks associated with international operations and expansion into new geographies.
• Cybersecurity incidents, data privacy, or other systems failures or disruptions.
• Currency fluctuations, inflation, interest rates, and broader macroeconomic conditions.
• Availability and cost of raw materials and other inputs.
• Ability to develop, launch, and protect new products and intellectual property.
• Reputation and relationships with customers and distributors, including the risk of customer loss.
• Substantial indebtedness and access to capital markets.
• Outcomes of litigation and other legal or regulatory proceedings.
• Deterioration in profitability or cash flows and potential asset impairments.
• Third-party supplier quality and manufacturing issues impacting the Animal Safety segment, with continued impact anticipated into fiscal year 2027.
• Product recall of Vet HyCoat Hyaluronate Sodium Sterile Solution due to microbial contamination, with ongoing legal claims and potential losses.

Future Outlook

The company expects continued impact from third-party supplier quality and manufacturing issues into the beginning of fiscal year 2027. Continued improvement in production inefficiencies for the sample collection product line is expected for the remainder of the current fiscal year. The sale of the Genomics business is expected to close by the end of the first half of fiscal year 2027. Capital expenditures for fiscal year 2026 are estimated at approximately $50.0 million.

Management Comments

• Management is optimistic about the company's long-term prospects.
• Management has initiated a restructuring plan to right-size the cost base through a reduction of approximately 10% in global headcount.
• Management believes that cash flows from operations, cash on hand, and borrowing capacity will enable the company to fund its operating business, repay debt, construct facilities, commercialize products, and execute strategic plans.
• Management intends to vigorously defend against legal proceedings.

Industry Context

StockSavvy.ai notes that Neogen's performance reflects broader trends in the food and animal safety sectors, including the impact of inflation on food production and a softening in the companion animal market. The divestiture of the genomics business aligns with a strategic focus on core competencies, a common move in the life sciences and diagnostics industry to streamline operations and enhance profitability.

Comparison to Industry Standards

• The decline in Animal Safety segment revenue (20.1% in Q3, 11.5% YTD) is concerning, as the animal health market, while cyclical, is generally expected to show resilience. Competitors like Zoetis (the acquirer of Neogen's genomics business) and Elanco have demonstrated more stable or growing revenues in their respective segments, though direct comparison is difficult without segment-specific data.
• The gross margin decline (46.9% in Q3 FY26 vs. 49.9% in Q3 FY25) is below the typical margins seen in specialized diagnostics and testing companies, which often operate in the 50-60%+ range. This suggests ongoing operational inefficiencies or pricing pressures.
• The reported net loss in the third quarter, while improved year-over-year on a nine-month basis, indicates ongoing challenges in achieving consistent profitability, a key benchmark for mature companies in the sector.

Corporate Governance

Legal Proceedings

• Putative class action complaint filed July 18, 2025, alleging false and misleading statements related to the integration of the 3M business.
• Putative class action filed August 27, 2025, alleging false and misleading statements in offering materials for the 2022 3M Food Safety Business acquisition.
• Three separate stockholder litigation demands received August 13, 15, and December 22, 2025, requesting investigation into allegations related to the 3M business integration.
• Putative shareholder derivative action filed December 4, 2025, alleging false and misleading statements and breaches of fiduciary duties related to the 3M business integration.
• Voluntary recall of Vet HyCoat Hyaluronate Sodium Sterile Solution initiated January 28, 2026, due to microbial contamination. Lawsuit filed March 25, 2026, related to the recalled product. Company believes it has strong defenses as a distributor, not manufacturer.

Stakeholder Impact

• Shareholders: Potential impact from ongoing litigation, material weaknesses in internal controls, and the strategic divestiture of the genomics business. Declining revenues and increased quarterly losses may affect investor confidence.
• Employees: Impacted by the planned 10% global headcount reduction as part of the restructuring initiative.
• Customers: Affected by the product recall of Vet HyCoat Hyaluronate Sodium Sterile Solution, with refunds being offered. Potential for supply chain disruptions or quality issues in the Animal Safety segment.
• Suppliers: May face increased scrutiny and more rigorous qualification processes due to identified third-party supplier quality and manufacturing issues.

Next Steps

• Complete the sale of the Genomics business to Zoetis Inc. by the end of the first half of fiscal year 2027.
• Conclude the initiated restructuring plan, which is expected to be completed in the fourth quarter of fiscal year 2026.
• Continue remediation efforts for material weaknesses in internal control over financial reporting.
• Implement a new, more rigorous supplier qualification and quality program to address manufacturing issues.

Key Dates

Recommendation

While the divestiture of the genomics business and the improvement in nine-month net income are positive steps, the continued decline in revenue, increased net loss in the current quarter, and persistent operational issues (supplier quality, manufacturing inefficiencies, internal control weaknesses) present significant headwinds. The company is in a transitional phase, and further clarity on the successful execution of restructuring and integration plans is needed before a more positive recommendation can be made.

Keywords

Neogen Corporation, 10-Q Filing, Quarterly Report, Food Safety, Animal Safety, Genomics Business Sale, Revenue Decline, Net Loss, Restructuring, Internal Controls, Zoetis Inc.